Kansas Venture Capital, Inc. (KVCI) has acquired the former AAIPharma
bioanalytical division from ZeeCRO Inc. With its 30-year track record of
developing entrepreneurial companies, KVCI will grow the bioanalytical
business through organic and acquisition strategies to provide
best-in-class analytical services for both the pharmaceutical and life
The new company is named KCAS, LLC, and will retain its location in
Shawnee, Kan. KVCI partnered with other local investors to acquire the
business. The Kansas Bioscience Authority provided strategic guidance
and will retain an advisory role in operations.
The original KCAS was founded in 1979 by William Mason, Ph.D., and
Robert Lanman, Ph.D., and this acquisition turns the lab back into an
independent entity in the Kansas City community.
Building on three decades of excellence, and more than 834 drug assays
and thousands of PK, TK and bioequivalence studies completed, KCAS’
mission is to elevate the quality of product development by providing
specialized small molecule, large molecule and biomarker analysis.
“We are excited to partner with KVCI and the Kansas Bioscience Authority
to bring our customer-focused culture and values back to both Kansas
City and the industries we serve,” said Dari Dadgar, Ph.D., who has led
the lab since 2005 and has been appointed the company’s president and
“In addition to providing access to significant capital resources, the
combined KVCI and KBA effort offers extensive pharmaceutical expertise
that will benefit our customers, employees and shareholders as we
continue to bring the highest levels of quality and innovation to the
marketplace,” said Michael Lanman, son of one of the original KCAS
founders and a 25-year veteran of the lab. Lanman will continue to serve
as the company’s lead operations executive.
For 30 years, KCAS has provided best-in-class bioanalytical services,
including method development, validation and high-throughput sample
analysis on biological samples from preclinical and clinical studies.
The company provides contract research services to pharmaceutical,
biotech, animal health and medical device companies to perform good
laboratory practices (GLP) and non-GLP bioanalytical analysis on blood,
plasma, urine and tissue samples. KCAS also has established a
quantitative method for the measurement of menstrual blood loss. This
method now is registered with the FDA, making KCAS a recognized leader
in this field.
With responsive, reliable and personalized results, KCAS boosts its
clients’ bottom lines by enabling them to get drugs to market more
quickly and effectively. The company serves pharmaceutical companies of
all sizes, including large multi-national companies, medium-sized
pharmaceutical and biotech organizations, and small or virtual companies.